Table 2.
Anti-inflammatory effects of compounds 1 to 7 on LPS-stimulated BMDCs.
| Compounds | IC50 Values (μM) a | ||
|---|---|---|---|
| IL-12 p40 | IL-6 | TNF-α | |
| 1 | 3.96 ± 0.12 | 4.07 ± 0.13 | >100 |
| 2 | 34.86 ± 1.31 | >100 | >100 |
| 3 | 6.55 ± 0.18 | >100 | 22.80 ± 0.21 |
| 4 | 5.06 ± 0.16 | 16.73 ± 0.25 | >100 |
| 5 | 1.82 ± 0.11 | 5.76 ± 0.14 | 4.94 ± 0.12 |
| 6 | 79.05 ± 2.05 | >100 | >100 |
| 7 | 3.90 ± 0.14 | 2.61 ± 0.10 | 7.00 ± 0.16 |
| SB203580 b | 5.00 ± 0.16 | 3.50 ± 0.12 | 7.20 ± 0.13 |
a IC50 values for selected compounds are given in column IL-12 p40, IL-6, and TNF-α; b Positive control; values <100 μM are considered to be active.